Tags

Type your tag names separated by a space and hit enter

A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management.

Abstract

INTRODUCTION

In recent years, there has been growing concern about an increasing rate of cardiovascular diseases in human immunodeficiency virus-infected patients, which could be associated with side effects of highly active antiretroviral therapy. It is likely that the metabolic disorders related to anti-human immunodeficiency virus treatment will eventually translate into a increased cardiovascular risk in patients submitted to such regimens.

OBJECTIVE

To evaluate if human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy are at higher risk of cardiovascular diseases than human immunodeficiency virus infected patients not receiving highly active antiretroviral therapy, or the general population.

RESEARCH DESIGN AND METHODS

We conducted a computer-based search in representative databases, and also performed manual tracking of citations in selected articles.

RESULT

The available evidence suggests an excess risk of cardiovascular events in human immunodeficiency virus-infected persons compared to non-human immunodeficiency virus infected individuals. The use of highly active antiretroviral therapy is associated with increased levels of total cholesterol, triglycerides, low-density lipoprotein and morphological signs of cardiovascular diseases. Some evidence suggested that human immunodeficiency virus-infected individuals on highly active antiretroviral therapy regimens are at increased risk of dyslipidemia, ischemic heart disease, and myocardial infarction, particularly if the highly active antiretroviral therapy regimen contains a protease inhibitor.

CONCLUSION

Physicians must weigh the cardiovascular risk against potential benefits when prescribing highly active antiretroviral therapy. Careful cardiac screening is warranted for patients who are being evaluated for, or who are receiving highly active antiretroviral therapy regimens, particularly for those with known underlying cardiovascular risk factors. A better understanding of the molecular mechanisms responsible for increased risk of cardiovascular diseases in human immunodeficiency virus-infected patients will lead to the discovery of new drugs that will reduce cardiovascular risk in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Universidade Federal da Bahia, Salvador, Bahia, Brazil. Electronic address: netofisio@gmail.com.

    ,

    Source

    MeSH

    Anti-HIV Agents
    Antiretroviral Therapy, Highly Active
    Cardiovascular Diseases
    Dyslipidemias
    Humans
    Myocardial Infarction
    Myocardial Ischemia
    Risk Factors

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    23916459

    Citation

    Neto, Mansueto Gomes, et al. "A Literature Review On Cardiovascular Risk in Human Immunodeficiency Virus-infected Patients: Implications for Clinical Management." The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases, vol. 17, no. 6, 2013, pp. 691-700.
    Neto MG, Zwirtes R, Brites C. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management. Braz J Infect Dis. 2013;17(6):691-700.
    Neto, M. G., Zwirtes, R., & Brites, C. (2013). A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management. The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases, 17(6), pp. 691-700. doi:10.1016/j.bjid.2013.05.004.
    Neto MG, Zwirtes R, Brites C. A Literature Review On Cardiovascular Risk in Human Immunodeficiency Virus-infected Patients: Implications for Clinical Management. Braz J Infect Dis. 2013;17(6):691-700. PubMed PMID: 23916459.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management. AU - Neto,Mansueto Gomes, AU - Zwirtes,Ricardo, AU - Brites,Carlos, Y1 - 2013/07/31/ PY - 2012/11/23/received PY - 2013/02/06/revised PY - 2013/05/08/accepted PY - 2013/8/7/entrez PY - 2013/8/7/pubmed PY - 2014/6/4/medline KW - AIDS KW - Cardiovascular diseases KW - Highly active antiretroviral therapy KW - Therapeutics SP - 691 EP - 700 JF - The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases JO - Braz J Infect Dis VL - 17 IS - 6 N2 - INTRODUCTION: In recent years, there has been growing concern about an increasing rate of cardiovascular diseases in human immunodeficiency virus-infected patients, which could be associated with side effects of highly active antiretroviral therapy. It is likely that the metabolic disorders related to anti-human immunodeficiency virus treatment will eventually translate into a increased cardiovascular risk in patients submitted to such regimens. OBJECTIVE: To evaluate if human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy are at higher risk of cardiovascular diseases than human immunodeficiency virus infected patients not receiving highly active antiretroviral therapy, or the general population. RESEARCH DESIGN AND METHODS: We conducted a computer-based search in representative databases, and also performed manual tracking of citations in selected articles. RESULT: The available evidence suggests an excess risk of cardiovascular events in human immunodeficiency virus-infected persons compared to non-human immunodeficiency virus infected individuals. The use of highly active antiretroviral therapy is associated with increased levels of total cholesterol, triglycerides, low-density lipoprotein and morphological signs of cardiovascular diseases. Some evidence suggested that human immunodeficiency virus-infected individuals on highly active antiretroviral therapy regimens are at increased risk of dyslipidemia, ischemic heart disease, and myocardial infarction, particularly if the highly active antiretroviral therapy regimen contains a protease inhibitor. CONCLUSION: Physicians must weigh the cardiovascular risk against potential benefits when prescribing highly active antiretroviral therapy. Careful cardiac screening is warranted for patients who are being evaluated for, or who are receiving highly active antiretroviral therapy regimens, particularly for those with known underlying cardiovascular risk factors. A better understanding of the molecular mechanisms responsible for increased risk of cardiovascular diseases in human immunodeficiency virus-infected patients will lead to the discovery of new drugs that will reduce cardiovascular risk in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. SN - 1678-4391 UR - https://www.unboundmedicine.com/medline/citation/23916459/A_literature_review_on_cardiovascular_risk_in_human_immunodeficiency_virus_infected_patients:_implications_for_clinical_management_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1413-8670(13)00154-2 DB - PRIME DP - Unbound Medicine ER -